|
Acute haemolytic anaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This drug is known to provoke acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
|
31525211 |
2019 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD deficient people.
|
31590661 |
2019 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The only licensed drug that kills hypnozoites is primaquine, which attacks the hypnozoite reservoir but imposes serious obstacles in doing so-at hypnozoitocidal doses, it invariably causes a threatening acute haemolytic anaemia in patients having an inborn deficiency in glucose-6-phosphate dehydrogenase (G6PD), affecting about 8% of people living in malaria endemic nations.
|
29357870 |
2018 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucose-6-phosphate dehydrogenase (G6PD) deficiency causes acute haemolytic anaemia triggered by oxidative drugs such as primaquine (PQ), used for Plasmodium vivax malaria radical cure.
|
26753754 |
2016 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common genetic abnormality known to predispose to acute hemolytic anemia (AHA), which can be triggered by certain drugs or infection.
|
27519946 |
2016 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies showed that glucose-6-phosphate dehydrogenase (G6PD) deficiency is a problem of public health importance that has been shown to be a predominant cause of acute hemolytic anemia requiring hospitalization in Palestinian young children in Gaza Strip.
|
27064064 |
2016 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
G6PD-deficient persons are mostly asymptomatic, but they can develop severe jaundice during the neonatal period and acute hemolytic anemia when they ingest fava beans or when they are exposed to certain infections or drugs.
|
27040960 |
2016 |
|
Acute haemolytic anaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rasburicase is contraindicated in G6PD-deficient patients due to the risk of AHA and possibly methemoglobinemia.
|
24787449 |
2014 |
|
Acute haemolytic anaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
That primaquine and other drugs can trigger acute haemolytic anaemia in subjects who have an inherited mutation of the glucose 6-phosphate dehydrogenase (G6PD) gene has been known for over half a century: however, these events still occur, because when giving the drug either the G6PD status of a person is not known, or the risk of this potentially life-threatening complication is under-estimated.
|
24372186 |
2014 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drug-induced acute hemolytic anemia in G6PD A- subjects can be life-threatening, depending on the nature and dosage of the drug trigger.
|
22993389 |
2012 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings imply a contribution of the UGT1A polymorphism associated to Gilbert's syndrome to development of the hyperbilirubinemia in G6PD deficient subjects during acute hemolytic anemia.
|
10359058 |
1999 |
|
Acute haemolytic anaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This paper describes a new glucose-6-phosphate-dehydrogenase variant discovered during the evaluation of an episode of acute hemolytic anemia in a 62-year-old black male, which was temporally related to the ingestion of Tolbutamide.
|
3369438 |
1988 |
|
Acute haemolytic anaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Favism is a severe, acute haemolytic anaemia which occurs in about 20% of G6PD deficient subjects after ingestion of fava beans.
|
6436490 |
1984 |